Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy

计划入组 10 人 · 首次发布于 2023 年 8 月 14 日

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

计划入组 17 人 · 首次发布于 2024 年 7 月 24 日

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

计划入组 30 人 · 首次发布于 2025 年 11 月 24 日

Lutetium (177Lu) zadavotide guraxetan

Lutetium-177 zadavotide guraxetan

Lutetium (177Lu) JH020002

177Lu-PSMA-I&T Demonstrates rPFS Benefit in mCRPC Patients in ECLIPSE Trial

Eli Lilly's Lutetium Zadavotide Guraxetan Shows Promise in Metastatic Castration-Resistant Prostate Cancer

Phase 3 ProstACT GLOBAL Trial Assesses 177Lu-TLX591 in Metastatic Castration-Resistant Prostate Cancer